International Center for Applied Biological Sciences (ICABS) offers different clinical genetic testing.
Diagnostic genetic test identifies whether an individual has a certain genetic disease. This test detects a specific gene alteration but is often not able to determine disease severity or age of onset. Thousands of diseases are caused by a mutation in a single gene. Examples include cystic fibrosis, hemochromatosis, and Huntington’s disease.
Proactive genetic test: Determines whether an individual has an increased risk for a particular disease. Test results indicate probability and are therefore less definitive since disease susceptibility may also be influenced by other genetic and non-genetic, environmental factors. Diseases that can be identified include certain forms of breast cancer and colorectal cancer.
Screening genetic test: An example of a genetic screening test is noninvasive prenatal testing (NIPT). NIPT, sometimes called noninvasive prenatal screening (NIPS), is a method of determining the risk that the fetus will be born with certain genetic abnormalities. This testing analyzes small fragments of DNA that are circulating in a pregnant woman’s blood. Unlike most DNA, which is found inside a cell’s nucleus, these fragments are free-floating and not within cells, and so are called cell-free DNA (cfDNA). Analyzing cfDNA from the placenta provides an opportunity for early detection of certain genetic abnormalities without harming the fetus.
Pharmacogenomics test: Identifies variations in an individual’s genetic makeup to determine whether a drug is suitable for that patient, and if so, what would be the safest and most effective dose.
Whole-genome and whole-exome sequencing: Examines the entire genome or exome to discover genetic alterations that may be the cause of disease. This test is most often used in complex diagnostic cases, but it is being explored for use in asymptomatic individuals to predict future (onset) disease.
Genome4All test
Genome4All test – find out if you have a higher risk of developing cancer, obesity and endocrinological and cardiovascular diseases.
Identifying family members at risk is one of the benefits of genetic testing. The potential result can be:
- variant of uncertain significance (VUS),
- pathogenic gene variant and
- benign gene variant
In case of a positive test result (when you have been diagnosed with a pathogenic gene variant or a variant of uncertain significance (VUS)), your family members have up to a 50% chance of having the same gene variant. Family testing can identify other family members who are at risk for the same medical condition.
Candidates for the Genome4All test are:
- children suffering from rare, hereditary diseases for the possibility of personalized treatment and children with rare diseases which were not yet been discovered by classical clinical examinations,
- individuals with the diagnosis who want to find out if there is a genetic cause for their condition and to check the possibility of personalized treatment,
- individuals with metabolic disorders who want to find out how their genes affect food metabolism and get guidelines for proper nutrition to maintain a healthy body weight,
- healthy individuals who want to find out the risk of developing cancer, heart disease, or find out how their genes affect food metabolism (nutrigenomics) and healthy individuals who have relatives in the family suffering from various types of cancer, heart disease, metabolic disorders, etc.
Genome4All test enables the detection of hereditary risk for the development of tumors of all organ systems, sudden cardiac death and cardiovascular diseases, obesity and endocrinological diseases. The test results reveal how your genes affect the metabolism of certain types of food. Using this test, you can create the most effective, personalized diet with the help of our experts.
A large number of cardiovascular diseases, which can lead to sudden cardiac death, have a genetic basis. Within risk groups in the population, in addition to standard clinical treatment following the guidelines of the European Society of Cardiology, it is necessary to perform a genetic screening, which will lead to optimization of treatment, but also a determination of recommendations related to further patient activities.